Medical Access and Reimbursement in Thailand

Thailand’s Ministry of Public Health issued a ministerial notification effective 23 April 2024 that reclassified certain plant-based substances (including psilocybin-containing mushrooms) so they can be used for medical treatment or research under the Narcotic Code; this explicitly enables clinical trials and regulated medical applications when permitted by the Thai regulatory framework. #

Regulatory body and process: the Food and Drug Administration (FDA), Ministry of Public Health, and the Narcotics Control Division are the authorities responsible for licensing research, hospital possession, and clinical use; approvals for clinical trials and any therapeutic use require formal institutional protocols, drug trial registration, and separate narcotics permits under Thai law. The Thai FDA’s narcotics control division oversees permits and monthly reporting requirements for controlled substances used in healthcare settings. #

Coverage and reimbursement: as of 20 February 2026 there is no public evidence that psilocybin-based interventions have entered routine reimbursement by Thailand’s public insurance schemes (e.g., the Universal Coverage/NHSO framework) or central drug-revolving procurement; access is therefore limited to sanctioned clinical trials or special compassionate-use programs that would likely be funded privately or by study sponsors rather than standard public reimbursement. Applications for therapeutic use would need to navigate clinical-trial approval pathways and any future inclusion in national formularies or the Narcotics Revolving Fund before public reimbursement becomes available. #

Notes on enforcement: despite the 2024 notification enabling medical/research use, Thai authorities have continued to publicly warn that “magic mushrooms” (psilocybin-containing) are controlled and that unauthorized possession/sale can attract criminal penalties; this reflects a transitional regulatory environment where authorized research and clinical programs are possible but recreational or unpermitted commercial activity remains prosecutable. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Esketamine (commercially known as SPRAVATO in many jurisdictions) is discussed in Thai regulatory circles and referenced in Thai narcotics/drug-control materials, but there is no clear public record (Thai FDA searchable drug registry) demonstrating a marketed product registration and routine public reimbursement in Thailand as of 20 February 2026. The Thai FDA’s narcotics-related pages and the national drug information portal are the competent sources for product registration and narcotics-revolving fund listings; the Narcotics Revolving Fund and FDA materials mention esketamine in policy/awareness contexts but do not constitute evidence of routine government reimbursement. # #

Clinical/medical context: globally, esketamine is an approved rapid-acting therapy for treatment-resistant depression under strict REMS-like programs; if a sponsor obtains Thai regulatory approval and the product is listed in the narcotics procurement or national formulary, it could be made available in licensed healthcare settings with supervised administration. As of the date above, there is no public evidence of inclusion in Thai public insurance formularies and therefore any use would be expected to be private/clinic-based or via sponsored clinical trials. #

Ketamine is a legally regulated medical anesthetic and analgesic in Thailand and is explicitly listed as a Category 2 psychotropic (a schedule that allows medical use but requires licensing/controls). As a hospital anesthetic it is widely used; psychiatric/psychedelic-style uses (subanesthetic infusions for depression) are practiced off-label in private and tertiary-care settings but are not generally included in routine public reimbursement for mental-health indications. # #

Regulatory and reimbursement nuance: because ketamine is a controlled substance (Category 2), possession and hospital use require appropriate licensing/record-keeping under the Thai FDA’s narcotics control rules; hospitals that administer ketamine must follow narcotics reporting and licensing (monthly reporting and permit rules are published by the Narcotics Control Division). Off-label psychiatric uses are typically provided in private clinics or hospital settings and are generally charged privately; public insurance reimbursement for ketamine as a psychiatric therapy would require formal inclusion in national formularies and guideline-based adoption, which had not been publicly documented as of 20 February 2026. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (DMT is listed among substances considered without medical use in Category 1/related lists in Thai narcotics/psychotropic summaries.) #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (No legal medical framework permitting routine therapeutic use or reimbursement was identified as of 20 February 2026.) #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (Ayahuasca preparations contain DMT and therefore fall under the same prohibitions; unregulated retreats in Thailand have been reported but carry legal and safety risk.) # #

Currently classified as a strictly controlled substance under national drug scheduling laws (listed among substances considered without medical use in Schedule I summaries), with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (Substituted phenethylamines such as the 2C family are treated under Thailand’s psychotropic/narcotics controls.) #